New Test Outperforms CA-125 in Ovarian Cancer Detection

Recent studies conducted in the United States and in Europe have effectively demonstrated the potential of a Parasortix-based blood test in outperforming current tests used to diagnose ovarian cancer. ANGLE, a world-leading liquid biopsy company, has currently invented a cell separation technology system known as Parasortix, which can be used to capture cancer cells circulating in the blood by performing simple blood tests. The Parasortix-based blood test involves taking a blood sample from a patient and capturing circulating tumor cells (CTCs) from the sample in a small microscope slide-like element. A reverse flow system then analyzes the viable cells and, once recognized, the RNA information within the cells are used to notify doctors about the patient’s condition and the most appropriate treatment method based on their individual case. More specifically, the blood test is used to make a distinction between benign and malignant tumors.  

A recent study conducted in the United States as well as in Europe effectively established the prospects of a Parasortix-based blood test in outdoing the current tests used to diagnose ovarian cancer. ANGLE is known to be one of the world’s leading liquid biopsy companies, and it has of late invented a cell separation technology system, which is called Parasortix. This system can be used to capture cancer cells circulating in the blood by carrying out a simple blood test. This Parasortix-based blood test involves taking a blood sample from the patient and then capturing the circulating tumor cells (CTCs) from the blood sample in a small microscope slide-like component. There is a reverse flow system which then analyzes the viable cells, and once they are identified, the RNA information present within the cells is then used to notify doctors about the condition of the patient as well as the most appropriate treatment option, depending on the case of the individual. This blood test is mostly used to find a distinction between benign and malignant tumors. The study of ANG-001 showed that the Parasortix-based blood test has the ability to differentiate between women suffering from ovarian cancer and those who have a non-malignant pelvic mass. With the help of the Parasortix system as well as a group of RNA markers, these women would be able to receive proper treatment and appropriate care. The data obtained from both the ANG-001 and ANG-003 studies also revealed that the best results could be achieved only by combining the selected genetic information along with certain kinds of information about the condition of the patient in an algorithmic form. This algorithm would then be further broken down as well as enhanced to provide the most precise results based on the medical needs of the patient.

The CA-125 is also being used for the detection of ovarian cancer. CA-125 is known to be a protein which is found in the blood. In several cases of women suffering from ovarian cancer, there were high levels of CA-125 found. When the scientists had compared both the Parasortix test along with CA-125, the Parasortix test clearly showed a nearly doubled specificity rate in comparison with the results of CA-125. A few of the positive aspects of this system can be seen in how easily the CTCs are harvested as well as analyzed, how easily and quickly the cancer cells can be captured, and also how this approach would not be based only on the use of antibodies. This system is inexpensive, it is easily accessible, and there is specific detailing involved with it as well. The Parasortix system has the potential to deliver personalized cancer care as well as offer improvements pertaining to clinical outcomes in the diagnosis and treatment of various types of cancers. It will also enable women suffering from ovarian cancer to be properly referred to institutions that are known to specialize in certain types of cancer and thus can provide them with the best kind of treatment.